Skip to content

Conventional TranArterial ChemoEmbolization (cTACE) for HCC

cTACE treatment involves the introduction of a cytotoxic drug, such as doxorubicin, epirubicin, idarubicin, mitomycin C, or cisplatin, which is mixed with the oily radio-opaque agent Lipiodol (Lipiodol® Ultra-Fluid, Guerbet), and injected directly into the affected artery. This is followed by the administration of an embolic agent, such as gelatin sponge, polyvinyl alcohol particles, or microspheres, through the same artery. The Lipiodol carries the chemotherapy to the tumor site, delivering the drugs directly to the cancer cells while also causing the tumor’s blood supply to be cut off due to embolization. The presence of Lipiodol in the tumor, as detected on post-procedure CT scans, has been linked to improved overall survival rates. As a result of these findings, cTACE has been widely recognized as the gold standard treatment for intermediate stage HCC, earning the highest grade of recommendation (1A) in 2012.

Case video and description:

A. Introduction: This video presents a detailed case report of an elderly female patient diagnosed with Hepatitis C Virus (HCV)-related Chronic Liver Disease (CLD) and a single large Hepatocellular Carcinoma (HCC) tumor with a size larger than 8 cm. The case highlights the therapeutic approach and management strategies in a complex clinical scenario.

B. Patient Profile: Age/Gender: Elderly Female Medical History: HCV-related CLD Diagnosis: Single large HCC (more than 8 cm in size), Lung lesion seen on MR imaging was confirmed to be of non-malignant etiology on PET-CT (images not shown) which resolved after 2 weeks of medical management.

C. Clinical Assessment: CHILD B Score: 7 ECOG Performance Status: 0 (fully active, able to carry on all pre-disease activities without restriction) STATE Score: Greater than 18, indicating feasibility for cTACE

D. Management and Treatment: Initiation of Lenvatinib Therapy: The patient was started on lenvatinib, a multi-kinase inhibitor that has shown efficacy in treating HCC. Lenvatinib is known for its ability to target tumor angiogenesis and proliferation. Combination Therapy with cTACE: Two weeks post-initiation of lenvatinib, the patient underwent conventional Transarterial Chemoembolization (cTACE). This decision was based on the tumor size and the patient’s overall condition. cTACE involves the direct delivery of chemotherapeutic agents (lipiodol mixed doxorubicin) to the liver tumor, combined with embolization with PVA particles that restricts the tumor’s blood supply.

E. Discussion: This case is significant due to the complexity of managing a large HCC in an elderly patient with underlying liver disease. The combination of lenvatinib and cTACE represents an integrated approach targeting both the tumor’s growth and its blood supply. The patient’s good performance status (ECOG 0) was a key factor in opting for this aggressive treatment strategy.

F. Conclusion: The case underscores the importance of a tailored approach in the management of HCC, especially in elderly patients with comorbidities. It highlights the need for a multidisciplinary team to assess and plan the treatment course in such complex scenarios.

Keypoints:

Blood supply patterns of HCC and lipiodol dosage:

TypeCT & DSA FindingsNourishing arteriesNotable FeaturesLipiodol Dosing
Type I - Abundant SupplyType Ia: Obvious homogeneous or non-homogeneous hyper-dense contrast in arterial phase and maintained enhancement through subsequent phases.

Type Ib: Slight enhancement, relative hypodense in arterial and portal-venous phases.
Type Ia: Radiated, piebald, petal, or tuberous broadened vessels.

Type Ib: Slightly broadened/nodular arteries; palisade shape enhancement in portal-venous phase.
Type Ia has more pronounced vessel features.

Type Ib shows subtler enhancements.
1. Depends on blood supply of tumor, patient’s condition, tolerance, catheter position. More lipiodol needed for abundant supply.
2. Non- selective embolization: Over 5 mL for <5 cm tumors, up to 10 mL for >5 cm, higher for larger tumors.
3. Super-selective embolization: Over 20 mL for <10 cm tumors, up to 30 mL or more for >10 cm, higher for larger tumors.
Type II - Poor SupplyNo or mild enhancement in all the phases.No or slight widening of nourishing arteries; absence of small vessels.Tumors show minimal response to contrast.1. Lipiodol dose should be minimal, as excess can disperse into normal liver parenchyma.
2. Overdosing may lead to deterioration of hepatic function especially in cirrhotic patients.
Type III - Mixed SupplyCombination of sufficient and poor blood supply areas.Areas with variable contrast enhancement.Co-existence of well-supplied and poorly-supplied areas within a single tumor.Depends on abundant blood supply area of tumor, patient’s condition, tolerance, catheter position.
Type IV - A-V ShuntEarly A-V shunt visibleEnlarged normal hepatic artery; A-V shunt evident.Special attention needed due to A-V shunt dynamics.Risk of pulmonary artery embolism in cases of hepatic arterial-venous fistula.
1. Lipiodol dose - 10 ml/m² body surface area
2. Lipiodol filling over 75% area of tumor is considered complete filling
3. Lipiodol filling 50%-70% area is considered comparatively complete filling

Contraindications:

Different Staging systems for HCC have slightly different exclusion criterias.

Method of Preparation:

Prepare water-in-oil emulsion (aqueous chemotherapy droplets in internal phase and Lipiodol in continuous external phase) to improve tumor deposit. 
The water-in-oil emulsion is obtained by mixing one volume of drug solution with two to three volumes of Lipiodol by pushing the drug syringe into the syringe containing Lipiodol.

Complications:

  1. Post Embolization Syndrome (Most common) – Presents as pain, fever, nausea, and vomiting. Managed using analgesic, antipyretic, antiemetic, and antibiotics depending upon patient’s symptoms post TACE
  2. Entry site complications (2-3%) – Hematoma, AV fistula, Pseudoaneurysm
  3. Vascular Complications (Rare) – Arterial dissection, thrombosis, Vasospasm
  4. Non-target embolization (Rare) – Chemical cholecystitis, Chemical pneumonitis
  5. Others (Rare)– Biloma, Abscess
  1. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. Journal of hepatology. 2015 May 1;62(5):1187-95.
  2. Wáng YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res. 2015 Apr;27(2):96-121. doi: 10.3978/j.issn.1000-9604.2015.03.03. PMID: 25937772; PMCID: PMC4409973.
  3. Guo T, Wu P, Liu P, Chen B, Jiang X, Gu Y, Liu Z, Li Z. Identifying the Best Anticancer Agent Combination in TACE for HCC Patients: A Network Meta-analysis. J Cancer. 2018 Jun 23;9(15):2640-2649. doi: 10.7150/jca.25056. PMID: 30087704; PMCID: PMC6072806.
  4. Aslaner R, Pekcevik Y, Sahin H, Toka O. Variations in the Origin of Inferior Phrenic Arteries and Their Relationship to Celiac Axis Variations on CT Angiography. Korean J Radiol. 2017 Mar-Apr;18(2):336-344. doi: 10.3348/kjr.2017.18.2.336. Epub 2017 Feb 7. PMID: 28246513; PMCID: PMC5313521
  5. Moustafa AS, Abdel Aal AK, Ertel N, Saad N, DuBay D, Saddekni S. Chemoembolization of Hepatocellular Carcinoma with Extrahepatic Collateral Blood Supply: Anatomic and Technical Considerations. Radiographics. 2017 May-Jun;37(3):963-977. doi: 10.1148/rg.2017160122. Epub 2017 Mar 31. PMID: 28362557.
  6. Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2013 Mar;30(1):3-11. doi: 10.1055/s-0033-1333648. PMID: 24436512; PMCID: PMC3700789.
  7. Cheng HY, Shou Y, Wang X, Xu AM, Chen D, Jia YC. Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol. 2004 Sep 15;10(18):2753-5. doi: 10.3748/wjg.v10.i18.2753. PMID: 15309735; PMCID: PMC4572209.
  8. Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000 Feb;214(2):349-57. doi: 10.1148/radiology.214.2.r00fe06349. PMID: 10671580.